Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

被引：3

作者：

Furman, Richard R. ^{[1
]}

Wierda, William G. ^{[2
]}

Schuh, Anna ^{[3
]}

Devereux, Stephen ^{[4
]}

Chaves, Jorge M. ^{[5
]}

Brown, Jennifer R. ^{[6
]}

Hillmen, Peter ^{[7
]}

Martin, Peter ^{[8
]}

Awan, Farrukh T. ^{[9
]}

Stephens, Deborah M. ^{[10
]}

Ghia, Paolo ^{[11
,12
]}

Barrientos, Jacqueline C. ^{[13
]}

Pagel, John M. ^{[14
]}

Woyach, Jennifer ^{[15
]}

Burke, Kathleen ^{[16
]}

Covey, Todd ^{[17
]}

Gulrajani, Michael ^{[18
]}

Hamdy, Ahmed ^{[18
]}

Izumi, Raquel ^{[18
]}

Frigault, Melanie M. ^{[18
]}

Patel, Priti ^{[18
]}

Rothbaum, Wayne ^{[18
]}

Wang, Min Hui ^{[18
]}

O'Brien, Susan M. ^{[19
]}

Byrd, John C. ^{[15
]}

机构：

[1] Weill Cornell Med, New York, NY USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Oxford, Dept Oncol, Oxford, England

[4] NHS Fdn Trust, Kings Coll Hosp, London, England

[5] Northwest Med Specialties PLLC, Tacoma, WA USA

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[7] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[8] Weill Cornell Med New York Presbyterian Hosp, New York, NY USA

[9] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

[10] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[11] Univ Vita Salute San Raffaele, Milan, Italy

[12] IRCCS San Raffaele Sci Inst, Milan, Italy

[13] Hofstra Northwell Sch Med, Hempstead, NY USA

[14] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[15] Ohio State Univ, Columbus, OH 43210 USA

[16] Oncol iMED AstraZeneca, Boston, MA USA

[17] Acerta Pharma, San Francisco, CA USA

[18] Acerta Pharma, San Francisco, CA USA

[19] UC Irvine, Chao Family Comprehens Canc Ctr, Orange, CA USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-128706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3039

引用

页数：5

共 50 条

[1] Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
Furman, Richard R.
Wierda, William G.
Schuh, Anna
Patten, Piers Em
Chaves, Jorge M.
Brown, Jennifer R.
Munir, Talha
Martin, Peter
Awan, Farrukh T.
Stephens, Deborah M.
Ghia, Paolo
Barrientos, Jacqueline C.
Patel, Krish
Woyach, Jennifer A.
Butturini, Anna
de Borja, Marianne
Wang, Min Hui
O'Brien, Susan
Byrd, John C.
BLOOD, 2022, 140 : 9873 - 9875
[2] Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 15 - 15
[3] Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
Byrd, John C.
Wierda, William G.
Schuh, Anna
Devereux, Stephen
Chaves, Jorge M.
Brown, Jennifer R.
Hillmen, Peter
Martin, Peter
Awan, Farrukh T.
Stephens, Deborah M.
Ghia, Paolo
Barrientos, Jacqueline
Pagel, John M.
Woyach, Jennifer A.
Burke, Kathleen
Covey, Todd
Gulrajani, Michael
Hamdy, Ahmed
Izumi, Raquel
Frigault, Melanie M.
Patel, Priti
Rothbaum, Wayne
Wang, Min Hui
O'Brien, Susan
Furman, Richard R.
BLOOD, 2020, 135 (15) : 1204 - 1213
[4] Acalabrutinib with obinutuzumab in treatmentnaive and relapsed/refractory chronic lymphocytic leukemia: 3-year follow-up
Woyach, Jennifer
Rogers, Kerry
Bhat, Seema
Blachly, James
Jianfar, Mojgan
Frigault, Melanie M.
Hamdy, Ahmed
Izumi, Raquel
Munugalavadla, Veerendra
Quah, Cheng
Wang, Min Hui
Byrd, John C.
LEUKEMIA & LYMPHOMA, 2020, 61 : 17 - 18
[5] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
O'Brien, Susan M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 22 - 23
[6] Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Rogers, Kerry
Thompson, Philip
Allan, John
Coleman, Morton
Sharman, Jeff
Cheson, Bruce D.
Izumi, Raquel
Frigault, Melanie M.
Quah, Cheng
Raman, Rakesh K.
Wang, Min Hui
Kipps, Thomas J.
LEUKEMIA & LYMPHOMA, 2020, 61 : 4 - 5
[7] Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: Three-Year Follow-Up
O'Brien, Susan M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 13 - 15
[8] Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Rogers, Kerry A.
Thompson, Philip A.
Allan, John N.
Coleman, Morton
Sharman, Jeff P.
Cheson, Bruce D.
Jones, Daniel
Izumi, Raquel
Frigault, Melanie M.
Quah, Cheng
Raman, Rakesh K.
Patel, Priti
Wang, Min Hui
Kipps, Thomas J.
HAEMATOLOGICA, 2021, 106 (09) : 2364 - 2373
[9] Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From the Phase 1/2 ACE-CL-001 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 14 - 16
[10] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study
Byrd, John C.
Wierda, William G.
Schuh, Anna
Devereux, Stephen
Chaves, Jorge M.
Brown, Jennifer R.
Hillmen, Peter
Martin, Peter
Awan, Farrukh T.
Stephens, Deborah M.
Ghia, Paolo
Barrientos, Jacqueline C.
Pagel, John M.
Woyach, Jennifer A.
Charuworn, Prista
Hamdy, Ahmed
Izumi, Raquel
Patel, Priti
Rothbaum, Wayne M.
Wang, Min Hui
Furman, Richard R.
BLOOD, 2017, 130

← 1 2 3 4 5 →